Synergistic interplay of lymphokines and double stranded rnas

Details Synergistic interplay of lymphokines and double stranded rnas Synergistic interplay of lymphokines and double stranded rnas

A - Human Necessities

61

K

167/103.2

A61K 38/19 (2006.01) A61K 38/20 (2006.01) A61K 38/21 (2006.01)

Patent

CA 1336810

The unexpected synergistic interplay between lymphokines and dsRNAs which dramatically reduces the necessary dosages of lymphokines, especially IL-2, and simultaneously widens their therapeutic range in the treatment of various types of cancers, viral disorders or other body conditions characterized by disregulated immune states (e.g., autoimmune diseases). Specific combinations of dsRNA plus IL-2 significantly increase survival in human melanoma-bearing animals in part because of augmentation by dsRNA of lymphokine activated killer cells (LAK) which are first formed in response to IL-2 exposure. The invention has wide applicability to non-toxic, efficacious control of both human cancer and various human viral infections and immunoregulatory disorders.

560249

Affiliated with

Also associated with

Rating

Synergistic interplay of lymphokines and double stranded rnas does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Synergistic interplay of lymphokines and double stranded rnas, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Synergistic interplay of lymphokines and double stranded rnas will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFCA-PAI-O-1172493